BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Jubilant FoodWorks to scrap Dunkin’ franchise arrangement in India - 2Favored Vehicle for Seniors: Make Your Determination
- 3Doctor's orders? ‘Belly laugh at least two to five days a week'
- 4Scientists solve the mystery of the prehistoric 'Burtele Foot'
- 5James Webb Space Telescope discovers a lemon-shaped exoplanet unlike anything seen before: 'What the heck is this?'
- Flu cases are spiking earlier than usual. What you need to know.
- 7 Delightful Ferris Wheels, Do You Like Them?
- What's your #1 tone
- Safeguarding Your Senior Protection Against Extortion and Tricks.
- The Magnificence of Extraordinariness: Presenting Valuable Adornments and Gemstones
- Mother and Stepson Rescued After Being Swept Over 6 Miles in Paddleboarding Mishap
- China's Normal Ponders: A Visual Excursion
- The Specialty of Cleaning up: Change Your Space and Brain
- Several injured as man threatens attack on German high-speed train
